The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62
Juan F. Linares, Tania Cid-Diaz, Ángeles Durán, Marta Osrodek, Anxo Martínez-Ordóñez, Miguel Reina‐Campos, Hui–Hsuan Kuo, Olivier Elemento, M L Collado Martín, Thekla Cordes, Timothy C. Thompson, Christian M. Metallo, Jorge Moscat, María T. Díaz‐Meco
Abstract
renders CAFs less active. PARP inhibitors, such as olaparib, mimick lactate in the reduction of stromal p62 levels, as well as the subsequent stromal activation both in vitro and in vivo, which suggests that therapies using olaparib would benefit from strategies aimed at inhibiting CAF activity.
Topics & Concepts
NAD+ kinaseCell biologyChemistryCancer researchBiologyBiochemistryEnzymeCancer-related Molecular PathwaysHistone Deacetylase Inhibitors ResearchMetabolism, Diabetes, and Cancer